Comparative Pharmacology
Head-to-head clinical analysis: ENTOCORT EC versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENTOCORT EC versus STERANE.
ENTOCORT EC vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory effects via inhibition of inflammatory mediators such as cytokines and prostaglandins.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
9 mg orally once daily in the morning for up to 8 weeks.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours; clinically, the extended intestinal release formulation maintains local activity despite short systemic half-life.
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Primarily fecal (60-70%) with minimal renal excretion (<10%); extensively metabolized hepatically, metabolites excreted in bile and feces.
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid
Corticosteroid